TheraVet Provides Its Half-year Operational Update Of 2021 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
(1)
Regulatory News:
TheraVet (ISIN: BE0974387194 ticker: ALVET), a biotechnology company specialising in osteoarticular treatments for animals, today announces a new use of BIOCERA-VET in a multidisciplinary approach to the treatment of osteosarcoma in dogs.
In addition to its ongoing clinical trial in appendicular osteosarcoma as a palliative alternative to limb amputation in dogs, TheraVet is currently evaluating the use of BIOCERA-VET as part of a comprehensive, multidisciplinary and curative approach to the treatment of osteosarcoma in dogs. This innovative treatment consists of a combination of tumour removal, reinforcement of the affected bone by cementoplasty and treatment of the cancer by immunochemical therapy, thus avoiding amputation.
TheraVet Extends the Use of BIOCERA-VET to a New Curative Approach of Osteosarcoma in Dogs Through a pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.